IDT Partners with Profluent Bio to Develop AI-Designed Enzymes
The collaboration combines Profluent’s generative AI platform with IDT’s enzyme engineering and genomics expertise to accelerate development of next-generation enzymes.
The collaboration combines Profluent’s generative AI platform with IDT’s enzyme engineering and genomics expertise to accelerate development of next-generation enzymes.
The DX-8 Series system combines CBC+DIFF, CRP, SAA, and HbA1c testing in a single platform with throughput up to 100 tests per hour.
Despite powerful advances in precision medicine, most doctors remain untrained in these emerging diagnostic tools.
The integration is designed to bridge specimen grossing with digital pathology workflows for improved diagnostic accuracy and efficiency.
The integration aims to address data volume management and standardization challenges in digital pathology workflows.
The ethyl alcohol assay categorization enables moderate complexity laboratories to expand drug screening capabilities on the Abbott analyzer platform.
The infrared dye antibody conjugates aim to expand human phenotyping experiments innovation and make high-parameter flow cytometry more accessible.
The DX-60 system offers 28 reportable parameters, malaria detection capabilities, and requires minimal sample volumes for testing.
Market growth driven by expanding clinical applications and regulatory innovation, with kits and reagents dominating product segments.
New instrument features StreamFocus ionization technology and AI-powered intelligence for enhanced sensitivity and efficiency in clinical laboratories.
Research-use-only assay identifies 28 urinary targets and 25 antibiotic resistance markers with same-day turnaround time.
Wasatch BioLabs expands service portfolio with pharmacogenomics panel, telomere sequencing, and mRNA vaccine quality control workflows.
The CLIA-waived immunoassay delivers results in as fast as 10 minutes and is designed for physician offices, urgent care centers, and decentralized hospital labs.
The sharp increase in fentanyl in random drug checks suggests more workers are using the opioid after they have passed pre-employment screens.